Article

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLC

2023-01-18

Abstract excerpt

Targeted therapy for lung cancer research has advanced quickly in recent years, particularly EGFR-TKIs in the grouping of EGFR-mutant lung cancer, however clinical treatment has encountered difficulties with acquired drug resistance. Due to their great specificity, few adverse reactions, and prolonged tumor control duration, immune checkpoint inhibitors PD-1 and PD-L1 antibodies have emerged as a new therapy appro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3fd3241f-c59b-5290-bdc6-368c2de9b8d8
DOI: 10.21203/rs.3.rs-2398118/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCDOI 10.21203/rs.3.rs-2398118/v1Read

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancerSemantic proximity Read

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.Semantic proximity Read

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsSemantic proximity Read

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.Semantic proximity Read

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.Semantic proximity Read

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.Semantic proximity Read

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIsSemantic proximity Read

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.Semantic proximity Read

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read

Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer.Semantic proximity Read